2Ford A,Moayyedi P.How can the current strategies for Helicobacter pylori eradication therapy be improved[J].Can J Gastroenterol,2003,17(SupplB):36B-40B.
6SanchezJ E,Saenz NG,Rincon MR,et al.Susceptibility of Helicobacter pylori to mupirocin,oxazolidinones,quinupristin/Dalfopristin and new quinolones[J].J Antimicrob Chemother,2000,46(2):283-285.
8Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther, 2007, 26 (3): 343-357.
9Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht Ⅲ Consensus Report. Gut, 2007, 56 (6): 772-781.
10Moayyedi P. Sequential regimens for Helicobacter pylori eradication. Lancet, 2007, 370 (9592): 1010-1012.
2CHEON J H, KIM N, LEE DH, et al. Trial of moxifloxacin - contai- ning triple therapy after initial and second -line treatment failures for helicobactor pylori infection [ J ]. Korean J Gastroenterol, 2005, 45(2) :111.
3SANCHEZJ E, SAENZ N G, RINCON M R, et al. Susceptibility of Hell - cobacter py[ori to mupirocin, oxazolidinones, quinupristin/ Dalfopristin and new quinolones [ J ]. J Antimicrob Chemother, 2000,46(2) :283 -285.
4VAIRAD,ZULLOA, VAKILN,et al. Sequential therapy standard triple - drug therapy for Helicobacrer pylori eradieation : arandomized trial[ J ]. Ann Intern Med,2007,146 ( 8 ) :556 - 563.
